<DOC>
	<DOCNO>NCT00852163</DOCNO>
	<brief_summary>The purpose study determine whether Clofarabine combination Busulfan effective preparative transplant regimen treatment leukemia myelodysplastic syndrome</brief_summary>
	<brief_title>Study Stem Cell Transplant Leukemia Myelodysplastic Syndromes Using Clofarabine Busulfan Regimen</brief_title>
	<detailed_description>The success allogeneic hematopoietic transplantation treatment myeloid malignancy determine two main factor : limit regimen-related toxicity prevention recurrent leukemia . Over past 10 year , considerable clinical research devote reduction regimen-related toxicity use reduced-intensity ( nonmyeloablative ) transplant . However , leukemic relapse remain difficult obstacle . Thus , need highly effective , yet non-toxic regimen persists , particularly elderly patient little overall progress make . Clofarabine chemotherapeutic agent novel myelotoxic property proven low toxicity old patient . These quality suggest clofarabine may useful component conditioning regimens stem cell transplantation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Disease Criteria : Acute myelogenous leukemia ( AML ) Acute lymphocytic leukemia ( ALL ) Myelodysplastic syndrome ( MDS ) Refractory anemia ( RA ) adverse cytogenetics ( SWOG criterion ) beyond ( RAEB , RAEBT , AML ) Other Myeloproliferative Disorders Myelofibrosis , Agnogenic Myeloid Metaplasia , Chronic Myelomonocytic Leukemia ( CMML ) Chronic lymphocytic leukemia ( CLL ) High risk advance disease Other 18 year age older Related unrelated donor HLA criterion follow : Related donor : serologic equivalent HLA Class I ( A , B , C ) Class II DRB1 DQB1 match donor OR donor single 1 antigen mismatch A , B , C , DRB1 , DQB1 locus Unrelated donor : sequencebased type fully match A , B , C , DRB1 , DQB1 allelematched donor OR donor great 1 antigen mismatch A , B , C , DRB1 , DQB1 loci Able provide valid inform consent . Female patient must negative serum pregnancy test within 2 week prior enrollment . Male female patient must use effective contraceptive method study 12 month study treatment . Organ Function Criteria : Cardiac : symptomatic coronary artery disease ejection fraction &lt; 45 % uncontrolled cardiac failure Pulmonary : FEV1 DLCO ( correct ) &lt; 50 % predict value and/or receive continuous supplementary oxygen Hepatic : Bilirubin ≥ 1.2 mg/dL AST/ALT ≥ 3x upper limit normal ( ULN ) unless liver involve malignant disease Renal : creatinine clearance &lt; 60 mL/min ( 24hour urine collection ) &lt; 50 mL/min ( Glofil test ) Karnofsky score &lt; 60 % Active CNS disease Prior hematopoietic transplantation ( autologous allogeneic ) &lt; 6 month prior study entry Use investigational agent less equal 30 day study entry . Life threatening , clinically significant infection Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Female patient pregnant breast feed HIVpositive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>conditioning , preparative</keyword>
	<keyword>clofarabine ; transplant</keyword>
	<keyword>Busulfan</keyword>
	<keyword>leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
</DOC>